http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102911124-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 |
| filingDate | 2012-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102911124-B |
| titleOfInvention | Hydroxypyrimidinone compound and its preparation method and application |
| abstract | The invention discloses a hydroxypyrimidinone compound, which has the structure shown in general formula (I): General formula (I), wherein, R 1 is tert-butyl, phenyl or substituted phenyl, substituted benzyl; R 2 is hydrogen or substituted propyl; R 3 , R 4 , R 5 , R 6 and R 7 are respectively independently hydrogen, methyl, methoxy, hydroxy or halogen; n is 1 or 2. The hydroxypyrimidinone compounds of the present invention have good HIV-1 integrase inhibitory activity and anti-HIV-1 virus activity, and the integrase inhibitory activity IC of compounds 5a, 5b, 5c, 5d, 5e, 5l, 5n, and 5q 50 are all less than or equal to 1 μM, compounds 5a, 5h, and 5s have strong antiviral activity, and their EC 50 are respectively 1.72, 1.91, and 1.3 μM, therefore, they can be used to prepare anti-AIDS drugs. |
| priorityDate | 2012-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.